Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MB-PD-102
- Development stage
- Preclinical
- Lead developer
- Mercury Bio
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
MB-PD-102 is an experimental intracellular immunotherapeutic being developed by Mercury Bio (Mercury Holdings) for the treatment of Parkinson's disease. It utilizes a nanobody modality designed to be delivered across the blood-brain barrier and into neurons. Once inside the cell, the nanobody is intended to modulate specific intracellular pathogenic proteins associated with the progression of Parkinson's disease. The drug is currently in the preclinical stage of development and is part of a pipeline focused on delivering large molecule therapeutics into the cytoplasm of target cells using a proprietary delivery system.
Beyond the preview
Go deeper on MB-PD-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MB-PD-102.